Find a company
Mogrify™ has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
Mogrify is leveraging this technology to identify small molecules capable of converting expandable cell types into chondrocytes in order to create a scalable supply of allogeneic chondrocytes for use in regeneration of the joints in cartilage defects and osteoarthritis.
| Project | Generation of chondrocytes by cell conversion for regenerative medicine applications |
|---|---|
| Description |
Mogrify™ has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state. Mogrify is leveraging this technology to identify small molecules capable of converting expandable cell types into chondrocytes in order to create a scalable supply of allogeneic chondrocytes for use in regeneration of the joints in cartilage defects and osteoarthritis. |
| Funding | £ 812,831 |
| Competition | Competition 15 - Improving Outcomes in Musculoskeletal Disorders |
| Competition Date | May 2019 |
| Website | https://mogrify.co.uk/ |